Table 1 Demographic and clinical characteristics

From: Intraindividual neurophysiological variability in ultra-high-risk for psychosis and schizophrenia patients: single-trial analysis

Variables

Healthy controls (n=28)

Ultrahigh risk (n=24)

Schizophrenia (n=21)

Analysis

df

 

Mean

s.d.

Mean

s.d.

Mean

s.d.

F or χ 2

 

Age (yrs)

23.64

4.09

21.29

3.1

23.67

4.33

3

2

Gender (m/f)

18/10

18/6

16/5

0.58

2

Education (yrs)

14.36

1.47

13.21

1.82

13.48

2.6

2.45

2

IQ

111.36

15.42

108.88

14.5

100.91

9.4

3.70a

2

Parental SES

2.89

0.88

3.17

1.17

2.62

0.74

1.87

2

PANSS

  

58.38

12.48

54.29

12.03

1.24

 

CAARMS

  

40.52

14.4

    

GAF

90.93

3.36

53.9

6.96

60.76

11.3

178.92a

2

HAMA

        

HAMD

        

CPZ doses (mg/day)

  

151.92

215.28

392.21

199.38

  

Neuroleptic medication (AP/AD/both/none)

   

(3/0/1/20)

(13/0/7/1)

 
  1. Abbreviations: AD, antidepressant; AP, antipsychotics; CAARMS, comprehensive assessment of at-risk mental states; CPZ, Chlorpromazine equivalent dose; df, degrees of freedom; f, female; GAF, Global Assessment of Functioning; HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton Depression Rating Scale; IQ, Intelligence Quotient; m, male; PANSS, Positive and Negative Syndrome Scale; SES, Socioeconomc Status; yrs, years.
  2. χ2 analysis for categorical data.
  3. aP<0.05.
Back to article page